Drug Development
UCLA Researcher Peter Tontonoz to Receive 2025 American Heart Association Basic Research Prize for Lipid Metabolism Discoveries
Dr. Peter Tontonoz's groundbreaking research on cholesterol and lipid metabolism has transformed understanding of cardiovascular diseases and paved the way for new treatments beyond statins.
Oncotelic Therapeutics Reports Two Years of Clinical Progress Across Oncology and Rare Disease Programs
Oncotelic Therapeutics has achieved significant clinical milestones over the past two years, advancing multiple late-stage programs including OT-101 for pancreatic cancer and OXi4503 for AML/MDS, positioning the company to address multi-billion-dollar markets with high unmet medical needs.
Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results
Kairos Pharma will present interim efficacy results from its Phase 2 trial of ENV105 in advanced prostate cancer, potentially addressing critical drug resistance challenges in oncology treatment.
Lantern Pharma CEO Discusses AI-Driven Cancer Drug Development on BioMedWire Podcast
Lantern Pharma's CEO Panna Sharma outlines the company's progress in using artificial intelligence to accelerate cancer drug development and transform oncology treatment approaches.
Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
Soligenix Receives FDA Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment
Soligenix Inc. has secured FDA orphan drug designation for its investigational therapy dusquetide, marking a significant advancement in treating Behçet's disease following promising phase 2a clinical trial results.
Oncotelic Therapeutics Highlights CEO's Track Record and Clinical Pipeline Advancements
Oncotelic Therapeutics showcases CEO Dr. Vuong Trieu's substantial patent portfolio and successful drug development history while updating progress on its oncology and immunotherapy pipeline.
Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
InFlectis BioScience and Aix Marseille Université Expand IFB-088's Therapeutic Potential to Axonal Charcot-Marie-Tooth Disease
InFlectis BioScience and Aix Marseille Université have demonstrated that lead compound IFB-088 shows efficacy in animal models of axonal Charcot-Marie-Tooth disease type 2A, expanding its potential to address multiple CMT subtypes with no approved treatments.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Creative Biolabs Advances Biopharmaceutical Innovation Through Glycobiology Expertise
Creative Biolabs is enhancing biopharmaceutical development through advanced glycoprotein engineering and polysaccharide analysis technologies that improve drug efficacy, safety, and stability.
Clene Inc. Advances Neurodegenerative Disease Treatment CNM-Au8® Toward Potential FDA Accelerated Approval
Clene Inc. is progressing its oral treatment CNM-Au8® for ALS and multiple sclerosis through late-stage clinical development, with key FDA meetings and regulatory catalysts potentially accelerating commercialization for patients with limited treatment options.
Zevra Therapeutics to Present New MIPLYFFA Data at International Congress, Including Best Poster Award Winner
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism, including a Best Poster award-winning presentation detailing its mechanism of action for treating Niemann-Pick disease type C, highlighting significant advancements in rare disease treatment.
Oncotelic Therapeutics Highlights Robust Oncology Pipeline and CEO's Patent Portfolio
Oncotelic Therapeutics showcases its clinical-stage oncology and immunotherapy pipeline, including multiple late-stage candidates and rare disease programs, while emphasizing CEO Dr. Vuong Trieu's extensive intellectual property contributions that underpin the company's competitive strategy.
Soligenix Advances Rare Disease Pipeline with Key Clinical Milestones Expected Through 2026
Soligenix Inc. reports significant progress in its late-stage rare disease treatments, including pivotal Phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies that could transform care for underserved patient populations.
Lantern Pharma Advances Oncology Pipeline with AI-Driven Clinical Progress and Extended Financial Runway
Lantern Pharma reports significant clinical trial advancements and AI platform enhancements while maintaining strong financial discipline, positioning the company for continued oncology drug development through mid-2026.
Clene Inc. Advances Toward NDA Submission for ALS Treatment CNM-Au8, Extends Financial Runway
Clene Inc. is preparing to submit a New Drug Application for its ALS treatment candidate CNM-Au8 by year-end 2025 while securing financial stability through recent financing that extends its cash runway into early 2026.
Sethera Therapeutics Announces Enzymatic Platform for Advanced Peptide Drug Development
Sethera Therapeutics has published research on an enzymatic platform that creates stable peptide structures, potentially enabling more effective and orally deliverable peptide therapeutics.
ReAlta Life Sciences Gains EMA Orphan Drug Designation for Graft-Versus-Host Disease Treatment
ReAlta Life Sciences received European Medicines Agency Orphan Drug Designation for its drug pegtarazimod, advancing a novel dual-targeting treatment approach for steroid-refractory acute graft-versus-host disease that addresses critical unmet medical needs.
Lantern Pharma Launches AI Tool predictBBB.ai to Revolutionize CNS Drug Development with 94% Accuracy
Lantern Pharma's new AI platform predictBBB.ai addresses the critical challenge of blood-brain barrier permeability in drug development, potentially accelerating treatments for neurological diseases with unprecedented 94% prediction accuracy.
BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
BioMed X and Novo Nordisk have partnered to tackle the challenge of oral peptide drug delivery, aiming to improve patient compliance and treatment efficacy through innovative formulation technologies.
Ascentage Pharma Advances Global Phase III Trial for Lisaftoclax in Higher-Risk MDS Treatment
Ascentage Pharma's GLORA-4 Phase III trial of lisaftoclax, a potential breakthrough for higher-risk myelodysplastic syndrome (MDS), receives FDA and EMA clearance, marking a significant step towards addressing a critical unmet medical need in oncology.
Soligenix Inc. Receives FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix Inc. has been granted FDA orphan drug designation for dusquetide, a significant step forward in treating Behçet’s Disease, highlighting the potential for new therapies in rare diseases.
Clene Inc. to Share Corporate Update at Emerging Growth Conference
Clene Inc. is set to present a corporate update at the Emerging Growth Conference, highlighting its progress in developing treatments for neurodegenerative diseases.
Clene Inc. Advances Toward FDA Submission for ALS Therapy with Promising Q2 2025 Results
Clene Inc. reports significant progress in its Q2 2025 results, targeting a year-end NDA submission for its ALS therapy, CNM-Au8, with sufficient cash runway into Q1 2026.
Intensity Therapeutics Pioneers New Cancer Treatment with Minimal Side Effects
Intensity Therapeutics is advancing a novel cancer treatment that directly targets tumors with minimal side effects, offering hope for patients with refractory solid tumors.
CNS Pharmaceuticals Inc. Advances TPI 287 Toward Phase 2 GBM Trial Amid Improved Financials
CNS Pharmaceuticals Inc. reports a slight improvement in Q2 2025 financials, with reduced net losses and increased R&D expenses as it prepares for a Phase 2 trial of TPI 287 for glioblastoma multiforme, highlighting the drug's potential to cross the blood-brain barrier and treat CNS tumors.
Creative Biolabs Introduces AI-Powered Solution to Revolutionize Drug Discovery
Creative Biolabs has launched an AI-powered end-to-end drug discovery solution aimed at addressing the challenges of high costs, failure rates, and lengthy timelines in drug R&D.